Poolbeg Pharma plc – Two posters with POLB 001 preclinical data presented at the European Hematology Association Congress
Posters highlight POLB 001’s potential in CRS prevention and ability to enhance AML treatment in elderly patients, potentially expanding into a new indication
· First poster shows that POLB 001 decreased key CRS-associated cytokines and did not impair bispecific antibody-induced tumour cell death in a series of preclinical investigations
· Second poster demonstrates the potential for POLB 001 to improve outcomes for elderly AML patients, positioning AML as a potential new indication for POLB 001
11 June 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces new research on two posters, by Poolbeg and The University of Manchester respectively, are being presented at the European Hematology Association Congress (“EHA”), in Stockholm, Sweden which runs from Thursday 11 June until Sunday 14 June 2026.
